Why you should subcribe
Alpha-1 Canada is working hard to increase the testing and diagnosis of Alpha-1 Antitrypsin Deficiency and lobbying for equitable access to treatment for Alphas across Canada.
Alpha-1 Canada cannot effectively campaign for treatment coverage to benefit Canadian Alphas without your help. By identifying the number of Canadians diagnosed with Alpha-1 we can produce the vital data required to educate provincial and territorial public drug programs on the benefits of treatment.
From time-to-time, Alpha-1 Canada sends electronic communications to enrollees to tell them about new clinical trial opportunities, networking/discussion groups, meetings, and other community based events for Alpha-1 patients and their families.
By enrolling with Alpha-1 Canada you agree to receive occasional electronic communications, understanding that you may unsubscribe at any time.